Navigation Links
Acridinium C2 NHS Ester from Assay Designs/Stressgen Bioreagents

ProductsAcridinium C2 NHS Ester from Assay Designs/Stressgen Bioreagents
Company Assay Designs/Stressgen Bioreagents
Item Acridinium C2 NHS Ester
Price $350.00
Description Acridinium esters have moderate chemiluminescence efficiencies and the chemistry of light production is well understood. They have the added benefit that they require simple triggering conditions that contribute little to the background signal. This benefit has been exploited to great effect in high sensitivity immunoassay applications. These compounds can also be easily modified to attach to proteins and other molecules of interest, without significantly affecting their chemiluminescence properties.
  • Simple NHS Chemistry
  • Direct, High Specific Activity Chemiluminescent Label
  • Labels Any Primary Amine Group
  • Can Be Read in Most Plate or Tube Luminometers
Info Assay Designs/Stressgen BioreagentsAssay Designs/Stressgen Bioreagents
5777 Hines Drive
Ann Arbor, MI 48108

Customer Service: (800) 833-8651
Fax Number: (734) 668-2793
Web Site: http://www.assaydesigns.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Acridinium NHS ester from Cayman Chemical
2. Acridinium NHS ester from Cayman Chemical
3. Acridinium Purification Buffer (10X) from Cayman Chemical
4. Acridinium Labeling Buffer from Cayman Chemical
5. Acridinium Ester Trigger Solutions from Assay Designs/Stressgen Bioreagents
6. Acridinium Quench Solution from Cayman Chemical
7. Glutathione-S-Transferase (GST) Colorimetric Assay Kit from Sigma-Aldrich
8. In Vitro Osteogenesis Assay Kit from CHEMICON
9. Mast Cell Degranulation colorimetric Assay Kit from CHEMICON
10. PR Competitor Assay Green from Invitrogen
11. PolarScreen Androgen Receptor Competitor Assay Kit, Red from Molecular Probes (Invitrogen)
(Date:6/11/2015)... , June 11, 2015 Daon, ... announced today that its IdentityX Mobile Authentication Platform ... IDentity Online) Alliance is an industry consortium launched ... standards for simpler, stronger authentication.  In order to ... pass a rigorous series of tests that measure ...
(Date:6/9/2015)... , June 9, 2015   MedNet Solutions ... the entire spectrum of clinical research, will be providing ... technology platform at the 2015 Drug Information Association (DIA) ... on June 15-17.  These presentations will include previews of ... out in the upcoming iMedNet 2015 Feature ...
(Date:6/8/2015)... , June 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... clinical data featuring its Precision Cancer Monitoring SM platform ... Liquid Biopsies conference in San Diego, CA ... Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy ... June 13-16. "We continue to advance our ...
Breaking Biology News(10 mins):Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4
... populating the growing brain, neural stem cells must strike a ... the cells multiply to provide plenty of starting materials ... If the stem cells proliferate too much, they could ... proliferate too little, there may not be enough cells to ...
... / b3c newswire / - KINAXO Biotechnologies GmbH ... service portfolio. KinAffinity provides invaluable information about a ... of interest. It simultaneously determines affinities for native ... overcomes the limitations of traditional biochemical assays that ...
... of researchers from the University of Maryland Center for ... study to forecast the effects of environmental change on ... by a $620,000 grant from the National Science Foundation, ... Preserve near Alexandria, Virginia. "Freshwater marshes are integral ...
Cached Biology News:UNC study pinpoints gene controlling number of brain cells 2KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue 2
(Date:7/2/2015)... 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... of intellectual property, today announced a litigation update. ... Verizon Services Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, ... District of Virginia , the Court ... certain key claims in favor of the Defendants on ...
(Date:7/2/2015)... Memphis, TN (PRWEB) , ... July 02, 2015 ... ... in the development and manufacturing of surgical instruments in Orthopedics, announced today the ... orthopedic contract-manufacturing and the world's largest provider of surgical instruments to the Spine ...
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus ... the development of groundbreaking drugs to treat neurodegenerative ... today that Robert G. Miller , M.D., Director ... Sutter Health,s California Pacific Medical Center in San Francisco, ... Association for $1.5 million to help fund a ...
Breaking Biology Technology:Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4